Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -47.45% | -34.84% | -33.15% | -30.45% | -11.19% |
| Total Depreciation and Amortization | 33.80% | 17.93% | 6.23% | -28.45% | -27.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.31% | 114.52% | 102.40% | 151.76% | 69.86% |
| Change in Net Operating Assets | -1.23% | -154.56% | -199.90% | -79.57% | -115.50% |
| Cash from Operations | -30.11% | -31.62% | -28.83% | -7.07% | -6.98% |
| Capital Expenditure | -114.08% | -162.00% | -535.10% | -659.49% | -433.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -302.33% | 117.28% | 107.55% | 129.51% | 137.83% |
| Cash from Investing | -324.21% | 111.71% | 103.01% | 126.66% | 135.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3,538.93% | -3,472.72% | -4,199.37% | -5,873.22% | -168.06% |
| Issuance of Common Stock | 2,956.00% | -93.84% | -95.27% | -96.98% | -97.05% |
| Repurchase of Common Stock | -149.74% | -175.82% | 87.43% | 86.83% | 90.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.33% | -12.50% | -12.50% | -62.50% | -70.00% |
| Cash from Financing | 1,293.78% | -36.57% | -43.64% | -62.07% | -92.24% |
| Foreign Exchange rate Adjustments | -7.00% | -954.55% | -442.11% | -496.12% | -3,517.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 259.54% | 227.22% | 267.34% | 443.38% | -193.80% |